Loading...
•
Sep 30, 2024
Dynavax Q3 2024 Earnings Report
Reported financial results and provided a business update.
Key Takeaways
Dynavax reported a 16% year-over-year increase in total revenues, reaching $80.6 million, with HEPLISAV-B net product revenue growing by 27% to $79.3 million. The company's net income was $17.6 million, or $0.13 per share basic and $0.12 diluted. They also announced a $200 million share repurchase program and discontinued the Tdap-1018 program to focus on long-term value creation.
HEPLISAV-B quarterly net product revenue reached $79.3 million, a 27% year-over-year increase.
The hepatitis B adult vaccine market is expected to expand to over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% market share.
Dynavax expects to achieve positive net income for the full year 2024, indicating full-year profitability.
The company's cash position strengthened to $764 million in Q3 2024.
Revenue by Segment
Forward Guidance
Dynavax updated its full year 2024 financial guidance, based on the Company’s current operating plan.
Positive Outlook
- HEPLISAV-B net product revenue range narrowed to approximately $265 to $270 million.
- HEPLISAV-B gross margin reiterated at approximately 80%.
- Research and development expense range reduced and narrowed to approximately $55 to $65 million.
- Selling, general and administrative expense range narrowed to approximately $170 to $180 million.
- Expect positive net income for full-year 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...